Genentech, Amgen settle Neupogen dispute
Executive Summary
Amgen will make a one-time payment to Genentech as part of a Neupogen and Neulasta patent dispute settlement reached Aug. 26. The terms of the settlement were not disclosed, but Genentech's expectation of a $0.20 per-share impact during the third quarter suggests a payment of approximately $105 mil. after taxes. Both sides have agreed to drop all claims and counterclaims. Amgen said it is not taking a license to any of the three disputed Genentech patents (1"The Pink Sheet" Nov. 11, 1996, T&G-3)...
You may also be interested in...
Genentech suit over Amgen's Neupogen alleges patent infringement.
GENENTECH SUIT OVER AMGEN NEUPOGEN PATENT INFRINGEMENT is an outgrowth of negotiations between the two California biotech giants over the use of recombinant gene technology. The suit, which was filed in San Francisco federal court Oct. 16, claims that Neupogen (filgrastim) uses "vectors, host cells and methods covered by the claims of Genentech's patents."
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.